Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 5, Pages 2847
Publisher
MDPI AG
Online
2022-03-07
DOI
10.3390/ijms23052847
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- GP96 and SMP30 Protein Priming of Dendritic Cell Vaccination Induces a More Potent CTL Response against Hepatoma
- (2022) Rongshi Huang et al. Journal of Healthcare Engineering
- The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts
- (2021) Qing Wu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients
- (2021) Valérie Gounant et al. Cancers
- PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
- (2021) Alessandro Rizzo et al. Cancers
- The role of exosomal PD-L1 in tumor immunotherapy
- (2021) Jing Wang et al. Translational Oncology
- Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy
- (2021) Mirjam de With et al. Cancers
- ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies
- (2021) Akiko Matsumoto et al. BMC CANCER
- Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
- (2021) Alexander Bagaev et al. CANCER CELL
- Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
- (2021) Xiaoxiang Zhou et al. LANCET ONCOLOGY
- Immunotherapy in Patients With Poor Performance Status: The Jury Is Still Out on This Special Population
- (2021) Ali Raza Khaki et al. JCO Oncology Practice
- Recent advances in primary resistance mechanisms against immune checkpoint inhibitors
- (2021) Yi-Ze Li et al. CURRENT OPINION IN ONCOLOGY
- Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
- (2020) M. Chalabi et al. ANNALS OF ONCOLOGY
- Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer
- (2020) A. Iglesias-Santamaría Clinical & Translational Oncology
- Immune-resistant mechanisms in cancer immunotherapy
- (2020) Yutaka Kawakami et al. International Journal of Clinical Oncology
- The biology, function, and biomedical applications of exosomes
- (2020) Raghu Kalluri et al. SCIENCE
- Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors
- (2020) Fabrice Barlesi et al. LANCET ONCOLOGY
- Exosomal PD-L1 induces immunosuppressive nonclassical monocytes
- (2020) Aaron A Diaz NEURO-ONCOLOGY
- Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
- (2020) Eli P. Darnell et al. Current Oncology Reports
- Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
- (2020) Harriet M. Kluger et al. Journal for ImmunoTherapy of Cancer
- Future Challenges in Cancer Resistance to Immunotherapy
- (2020) Marit J. van Elsas et al. Cancers
- PD-L1+ exosomes from bone marrow-derived cells of tumor-bearing mice inhibit antitumor immunity
- (2020) Yan Sun et al. Cellular & Molecular Immunology
- Mechanisms of Cancer Resistance to Immunotherapy
- (2020) Rilan Bai et al. Frontiers in Oncology
- Future of immune checkpoint inhibitors: focus on tumor immune microenvironment
- (2020) Yunlong Jia et al. Annals of Translational Medicine
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
- (2019) Jérôme Galon et al. NATURE REVIEWS DRUG DISCOVERY
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Surprisingly Positive Association Between Obesity and Cancer Immunotherapy Efficacy
- (2019) William J. Murphy et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
- (2019) Mauro Poggio et al. CELL
- PD-L1 expression of lung cancer cells, unlike infiltrating immune cells, is stable and unaffected by therapy during brain metastatization
- (2019) Vanda Téglási et al. Clinical Lung Cancer
- Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action
- (2019) Ni Zhang et al. Immunotherapy
- Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
- (2019) Yucai Wang et al. JAMA Oncology
- Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
- (2019) Davide Bedognetti et al. Journal for ImmunoTherapy of Cancer
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?
- (2019) V Simmet et al. ANNALS OF ONCOLOGY
- Checkpoint Genes at the Cancer Side of the Immunological Synapse in Bladder Cancer
- (2019) Paula Dobosz et al. Translational Oncology
- Mechanisms of Intrinsic Tumor Resistance to Immunotherapy
- (2018) John Rieth et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
- (2018) Fabio Conforti et al. LANCET ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity
- (2018) Huanbin Wang et al. Nature Chemical Biology
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
- (2017) Marta Łuksza et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
- (2017) Robert T. Manguso et al. NATURE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
- (2017) Whijae Roh et al. Science Translational Medicine
- In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
- (2017) Sean P. Arlauckas et al. Science Translational Medicine
- IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting
- (2017) Kazuyoshi Takeda et al. Nature Communications
- Calreticulin Expression in Human Non–Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis
- (2016) Jitka Fucikova et al. CANCER RESEARCH
- Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency
- (2016) F. Zhao et al. CANCER RESEARCH
- Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis
- (2016) Tomohiro F. Nishijima et al. CANCER TREATMENT REVIEWS
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition
- (2016) Carolina Pereira et al. CLINICAL CANCER RESEARCH
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
- (2016) Nan Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
- (2016) Wei Yang et al. NATURE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer
- (2016) J Li et al. ONCOGENE
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
- (2016) Marios Giannakis et al. Cell Reports
- PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer
- (2015) Nisha Nagarsheth et al. CANCER RESEARCH
- CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
- (2015) B. G. Leclerc et al. CLINICAL CANCER RESEARCH
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- Loss of tapasin correlates with diminished CD8+ T-cell immunity and prognosis in colorectal cancer
- (2015) Lena Sokol et al. Journal of Translational Medicine
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- (2015) Siwen Hu-Lieskovan et al. Science Translational Medicine
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
- (2015) D. S. Thommen et al. Cancer Immunology Research
- CD73: A potential biomarker for anti-PD-1 therapy
- (2015) Paul A Beavis et al. OncoImmunology
- Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism
- (2014) Minjie Gao et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer
- (2014) Steffen Rausch et al. Human Vaccines & Immunotherapeutics
- Cellular and molecular mechanisms in cancer immune escape: a comprehensive review
- (2013) Alka Bhatia et al. Expert Review of Clinical Immunology
- Anti-CD73 therapy impairs tumor angiogenesis
- (2013) Bertrand Allard et al. INTERNATIONAL JOURNAL OF CANCER
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
- (2012) M. Platten et al. CANCER RESEARCH
- Liver X receptor biology and pharmacology: new pathways, challenges and opportunities
- (2012) Tomas Jakobsson et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
- (2010) Kai Kessenbrock et al. CELL
- Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis
- (2010) Mao Mao An et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients
- (2010) S. Wu et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
- (2010) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The chemokine system in cancer biology and therapy
- (2009) Alberto Mantovani et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression
- (2009) Ethan M. Shevach IMMUNITY
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
- Cellular cholesterol trafficking and compartmentalization
- (2008) Elina Ikonen NATURE REVIEWS MOLECULAR CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More